News
-
-
-
PRESS RELEASE
Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides
NanoViricides, Inc. starts enrolling patients in Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebolavirus in DRC. Trial aims for safe dosing protocol and efficacy evaluation for Ebola virus infection -
-
-
PRESS RELEASE
Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
NanoViricides, Inc. initiates Phase II Clinical Trial of Novel Antiviral Drug NV-387 for Monkeypox in DRC led by Prof. Vivi Maketa Tevuzula. Trial aims to evaluate safety and efficacy, potential impact on pandemic response -
-
-
PRESS RELEASE
Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides
NanoViricides, Inc. announces the start of a Phase II Clinical Trial for NV-387 Oral Gummies as a Treatment for Ebola in DRC. NV-387 offers broad-spectrum antiviral properties against Ebola viruses -
